Physician profile
Robert Bernard
NPI 1023098464
$3,866.82
in general payments reported to CMS, 2019-2025
29 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $419 · 2021: $496 · 2022: $692 · 2023: $668 · 2024: $604 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $823.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $417.27 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.03 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $379.92 | 2020-2025 | |
| Lilly USA, LLC | $373.26 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $240.93 | 2019-2024 | Xarelto |
| Idorsia Pharmaceuticals US INC | $172.05 | 2023-2024 | Quviviq |
| Abbvie INC. | $171.31 | 2021-2022 | |
| Glaxosmithkline, LLC. | $136.11 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $83.30 | 2022-2024 | Repatha, Otezla |
| Allergan, INC. | $78.47 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.94 | 2022 | |
| Bausch Health US, LLC | $68.60 | 2019-2021 | |
| Antares Pharma, INC. | $62.33 | 2019-2024 | Xyosted |
| Heartflow, INC. | $50.16 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $41.78 | 2023-2025 | Cologuard Collection Kit |
| Orexo US, INC. | $41.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.78 | 2019 | |
| Abbott Laboratories | $32.67 | 2022-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $30.67 | 2021 | |
| Indivior INC. | $24.26 | 2025 | Sublocade |
| Avvisto Therapeutics, LLC | $23.65 | 2024 | Cycloset |
| Kowa Pharmaceuticals America, INC. | $23.03 | 2022 | |
| Clarus Therapeutics INC. | $22.39 | 2021 | |
| Arbor Pharmaceuticals, INC. | $20.09 | 2019 | |
| Acerus Pharmaceuticals Corporation | $18.81 | 2022 | |
| Astellas Pharma US INC | $16.41 | 2019 | |
| Circassia INC. | $15.11 | 2019 | |
| Amarin Pharma, INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.